CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc. is establishing a mixed-shelf registration that permits the offer and sale of up to $250,000,000 of common stock, preferred stock, warrants, rights and units over time. Within this capacity, it has also arranged an at-the-market program with Cantor Fitzgerald & Co. to sell up to $100,000,000 of common stock on Nasdaq under the symbol CV.
The ATM shares are part of, not in addition to, the $250,000,000 shelf. As of June 30, 2026, CapsoVision had 50,032,148 common shares outstanding, with additional shares reserved under options, warrants, RSUs and its 2025 Equity Incentive Plan. The company states it will use any proceeds primarily for general corporate purposes, including sales and marketing, research and development, administrative expenses and working capital.
CapsoVision describes itself as a commercial-stage medical technology company focused on GI-tract capsule endoscopy, with 2025 revenue of $13.6 million mainly from its CapsoCam Plus capsule. The shelf and ATM provide flexibility to raise equity capital as needed, at prices determined by future market conditions.
CapsoVision, Inc. develops capsule endoscopy and AI-based imaging solutions for gastrointestinal diagnostics, led by its CapsoCam Plus small-bowel capsule and in-development CapsoCam Colon and CapsoCam UGI systems. For the quarter ended June 30, 2026, net revenue was $3.64 million versus $3.32 million a year earlier, while the operating loss widened to $7.58 million from $4.65 million. For the first six months of 2026, revenue was $6.44 million and net loss was $14.51 million.
Cash and cash equivalents were $9.08 million as of June 30, 2026, after using $14.47 million in net cash for operating activities in the first half. The company raised approximately $14 million of gross proceeds in a March 2026 private placement of 2,867,089 common shares at $4.883 per share, and later put in place a $100 million at-the-market equity program with a sales agent. Management states that, despite these financings, there is substantial doubt about its ability to continue as a going concern within one year without additional capital.
The pipeline includes a second-generation CapsoCam Colon capsule, with a pivotal study of 801 patients completed and a 510(k) submission targeted for the fourth quarter of 2026, and AI enhancements to CapsoCam Plus, for which FDA clearance is anticipated by the end of the third quarter of 2026. The company is also running an early pancreatic cancer study using its CapsoCam UGI system and plans to resubmit a Breakthrough Device Designation request after additional data are collected.
CapsoVision, Inc. entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market equity program under which it may sell up to $100,000,000 of common stock from time to time. Cantor will act as sales agent or principal for a commission of up to 3.0% of gross proceeds. The company plans to use a Form S-3 shelf registration and an at-the-market prospectus supplement for these potential issuances.
For the quarter ended June 30, 2026, CapsoVision reported revenue of $3.6 million, up about 10% year over year, driven by a 13% increase in CapsoCam Plus capsule volume, partly offset by lower average selling prices. Gross margin was 51%, down from 55% a year earlier due to pricing pressure and higher customs and tariff costs. Operating expenses rose to $9.5 million, mainly from clinical trials, development work and public company costs, leading to an operating loss of $7.6 million and a net loss of $7.5 million.
Cash and cash equivalents were $9.1 million as of June 30, 2026, with net cash used in operating activities of $14.5 million in the first half of 2026. Operationally, management highlighted international launch of its AI Highlights feature, broader hospital and GI network adoption, over 176,000 patients having used CapsoCam Plus, and pipeline progress including anticipated FDA clearance of AI Highlights by the end of the third quarter of 2026 and a planned 510(k) submission for CapsoCam Colon in the fourth quarter of 2026.
CapsoVision, Inc reported that the Harari Family Trust, for which Eliyahou Harari and his wife serve as trustees, purchased 61,068 shares of common stock on 2026-07-17 at $6.73 per share in an open-market or private transaction, increasing its indirect holdings to 3,343,119 shares.
CapsoVision, Inc insider Harari Eliyahou et al, identified as a ten percent owner, reported an open-market purchase of 81,300 shares of common stock at $6.09 per share on July 8, 2026. The shares are held indirectly through the Harari Family Trust, where the reporting person and spouse serve as trustees, bringing the reported indirect holdings to 3,282,051 shares after this transaction.
CapsoVision, Inc insider holdings increased through an indirect open-market purchase. On June 26, 2026, the Harari Family Trust, for which the reporting person and his wife are trustees, bought 13,850 shares of CapsoVision common stock at $7.351 per share. After this transaction, the trust held 3,200,751 shares in total.
Shields David Stanley reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director David Stanley Shields received a grant of 1,710 Restricted Stock Units (RSUs). The award was reported at a price of $0.0000 per unit, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents a contingent right to receive one share of CapsoVision common stock, and these RSUs are scheduled to vest on December 31, 2026. Following this grant, Shields is reported as directly holding 1,710 RSUs linked to common stock.
CapsoVision, Inc director David Stanley Shields filed an initial ownership report on Form 3. The filing indicates that he does not beneficially own any shares of CapsoVision common stock, as confirmed by a footnote stating that no securities are beneficially owned.
CapsoVision, Inc. appointed gastroenterologist Dr. David S. Shields to its Board of Directors as a Class I director and member of the Compensation Committee, effective July 1, 2026, filling the vacancy created by the resignation of Dr. Joanne Imperial.
The Board determined that Dr. Shields is an independent director and he will receive the company’s standard non-employee director compensation and a standard indemnification agreement. Separately, CapsoVision entered into a consulting agreement under which Dr. Shields will provide clinical consulting and industrial affiliation services at US$600 per hour for up to 3 hours per work week.
Dr. Imperial stepped down from the Board and the Compensation Committee, effective July 1, 2026, without any disagreement regarding the company’s operations, policies or practices. Under an amended and restated consulting agreement dated July 2, 2026, she will continue as an independent consultant at US$600 per hour for up to 5 hours per work week and received an option to purchase 10,000 shares of common stock, vesting over four years, as compensation for her services.
CapsoVision, Inc director Joanne Carol Imperial reported a routine equity compensation event. On June 30, she exercised previously granted Restricted Stock Units (RSUs), receiving 2,022 shares of common stock at no cash cost to her as part of an equity incentive grant.
The filing shows she now directly owns 3,709 shares of CapsoVision common stock. The RSU award was originally granted on March 19, 2026 using a fair market value of $6.18 per share, and vests in two installments each year, with this report reflecting the June 30 vesting portion.